Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.

Abstract

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.

• Authors: Zhen-gang Yuan, Xiao-yi Dun, Yong-hua Li, Jian Hou
• Journal: Journal of hematology & oncology (J Hematol Oncol) Vol. 2 Pg. 19 (Apr 28 2009) ISSN: 1756-8722 [Electronic] England
• PMID: 19400935 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Boronic Acids
• Pyrazines
• Bortezomib

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Boronic Acids (therapeutic use)
• Bortezomib
• Castleman Disease (complications, drug therapy, pathology)
• Humans
• Male
• Multiple Myeloma (complications, drug therapy, pathology)
• Neoplasms, Multiple Primary (drug therapy, pathology)
• Pyrazines (therapeutic use)
• Remission Induction